Tarsus Pharmaceuticals, Inc. Share Price & Technical Analysis
TARS · $62.26 (-1.92%)
Healthcare / Biotechnology
$62.26
-1.92%
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as wel…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-1% return in May, 0% avg return in past 3 year May month.
-19% return in 2026, 82% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -21% | 17% | -5% | -10% | -1% | – | – | – | – | – | – | – | -19% |
| 25 | -4% | -15% | 16% | 1% | -17% | -7% | -4% | 51% | 2% | 17% | 16% | 3% | 59% |
| 24 | 36% | 39% | 5% | -14% | 5% | -19% | -11% | 12% | 22% | 35% | 17% | 6% | 134% |
| 23 | 8% | -2% | -18% | 17% | 12% | 8% | 22% | -13% | 1% | -19% | 15% | 21% | 52% |
| 22 | -13% | -12% | -6% | 8% | -18% | 5% | 3% | -3% | 12% | 6% | -10% | -12% | -42% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.57B
P/E ratio
—
52W high
$85.25
52W low
$38.51
Volume
2,59,588
Beta
0.53
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Tarsus Pharmaceuticals, Inc. share price today?
- Tarsus Pharmaceuticals, Inc. (TARS) last traded around $62.26 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does TARS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for TARS. Download the app for real-time alerts.
- How can I analyze Tarsus Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.